Trial Profile
A Phase II Study of Neoadjuvant Sunitinib in Metastatic Renal Cell Carcinoma
Status:
Discontinued
Phase of Trial:
Phase II
Latest Information Update: 18 Jul 2023
Price :
$35
*
At a glance
- Drugs Sunitinib (Primary)
- Indications Renal cell carcinoma
- Focus Therapeutic Use
- Acronyms NeoSun
- 22 Sep 2021 Results of an analysis focusing on dynamic biomarker and imaging changes published in the BJU International
- 18 May 2019 Status changed from recruiting to discontinued.
- 06 Jun 2017 Results (n=14) presented at the 53rd Annual Meeting of the American Society of Clinical Oncology